Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 12/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201020 | 0.80 | HTT (0.41) | MAPK13MAPK12MAPK11MAPK14GRM4 | |
| SCHEMBL2201628 | 0.79 | MAPK14 (0.42) | MAPK13MAPK12MAPK11MAPK14GRM4 | |
| SCHEMBL2196276 | 0.78 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14GRM4 | |
| SCHEMBL2199410 | 0.75 | KDM4E (0.51) | MAPK14TP53 | |
| SCHEMBL2199363 | 0.74 | MAPK14 (0.56) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2198443 | 0.74 | MAPK14 (0.56) | MAPK13MAPK12MAPK11MAPK14GRM4 | |
| SCHEMBL2198769 | 0.74 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL2200750 | 0.74 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL2200077 | 0.74 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL27494655 | 0.73 | MAPK13 (0.52) | MAPK13MAPK12MAPK11MAPK14MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658263-B9 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2011-11-09 | — | — | EP | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| EP-1658263-B1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-06-02 | — | — | EP | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | MAPK13 1063/4885MAPK12 955/4885MAPK11 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.